Carrington Laboratories, Inc. announced the results of its Phase III pivotal trial with Aliminase for ulcerative colitis. Indications were that no significant differences were found to support a therapeutic drug effect. In light of these results, the company plans to discontinue the development and testing of Aliminase as a treatment for ulcerative colitis. “Although we Read more about Carrington Announces Results Of Aliminase Clinical[…]
Antisoma PLC has adopted a new clinical programme around Therex, a product based on the humanised monoclonal antibody huHMFG1 aiming to treat breast cancer. Originally developed by the Imperial Cancer Research Fund (ICRF), Therex is in a Phase I clinical study. The antibody targets most common epithelial cancers, including breast, lung, ovarian, gastric and colorectal Read more about Antisoma Adopts Therex From Imperial Cancer Research Fund[…]
Gone are the days when a great physique was a characteristic feature of people serving in the armed forces or sports persons or athletes. The modern world in a health conscious world where a physically fit body is considered to be one of the most valuable assets that a human being can possess or is Read more about Synthobolic Extreme Synthol – Guaranteed Size and Muscle Definition[…]
Epimmune Inc. announced that the U.S. Patent and Trademark Office has issued the Company a patent relating to the Company’s core vaccine technology. The patent is U.S. Patent Number 6,037,135 entitled “Methods of Making HLA Binding Peptides and Their Uses,” and it includes claims covering methods for using any genomic or protein sequence to discover Read more about Epimmune Receives Patent For Vaccine Technology[…]
Techniclone Corporation was issued U.S. Patent No. 6,036,955 on March 14, 2000 entitled “Kits and Methods for the Specific Coagulation of Vasculature” by the U.S. Patent and Trademark Office. This patent covers particular methods of inducing molecules on tumour blood vessels for subsequent targeting and destruction and is a valuable addition to Techniclone’s existing broad Read more about Techniclone Issued Patent Extending Vascular Targeting Agent Portfolio[…]
Crescendo Pharmaceuticals Corporation has announced that ALZA Corporation has exercised its option to obtain a worldwide license to DUROS leuprolide (Viadur), a once-yearly implant for the palliative treatment of advanced prostate cancer. DUROS leuprolide is the first product to provide continuous, 12-month testosterone suppression with a single treatment. Under the terms of its license agreement Read more about Alza Exercises Option For Cancer Treatment[…]
Cellegy Pharmaceuticals, Inc., has initiated a second Phase III clinical trial to provide confirmatory evidence that Anogesic (nitroglycerin ointment) reduces the average daily pain associated with anal fissures. Initiation of this trial follows review by the US FDA of the study protocol and the results of a recently completed Phase III trial. In the recently Read more about Cellegy Begins Phase III Clinical Trial With Anogesic[…]
EntreMed, Inc. announced that U.S. Patent No. 6,025,688 has been issued covering all antiangiogenic fragments and methods of production for its potent angiogenesis inhibitor, angiostatin protein. The patent also covers antiangiogenic fragments of angiostatin protein that may contain amino acid additions, deletions, or substitutions, which means that any products developed through alterations to the parent Read more about EntreMed Issued Broad Angiostatin Patent[…]
Carrington Laboratories, Inc., and Medline Industries, Inc., have formed a distribution licensing agreement under which Carrington has granted Medline the exclusive rights to sell and market Carrington’s wound and skin care products, the companies have announced. Carrington estimates the value of this agreement to be approximately $50 to $60 million over the five-year term of Read more about Carrington And Medline Sign Licensing Distribution Agreement[…]
AngioSense Inc., and Boston-based Repair Inc. are to jointly pursue clinical applications for sustained delivery of fibroblast growth factor (FGF) to stimulate the growth of new blood vessels in diseased hearts. Under the agreement, AngioSense will supply its needle-free, jet injection delivery systems and Repair will provide proprietary FGF protein and fibrinogen constructs. Financial details Read more about AngioSense And Repair Agree Cardiovascular Collaboration[…]